
|Videos|August 26, 2021
Part 1: IDH1 & IDH2 Inhibitors In Newly Diagnosed AML
Alexandra S. Wolff, PharmD, BCOP, discusses use of IDH1 and IDH2 inhibitors in newly diagnosed AML patients and highlights recently released trial data.
Advertisement
Episodes in this series

Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
Tradipitant Becomes First Treatment Approved for Vomiting Due to Motion Sickness in 4 Decades
2
Expanding Access to MOUD: The Psychiatric Pharmacist’s Role in Optimization
3
Aspirin Dosage and Decision-Making: What Pharmacists Should Know
4
Psychiatric Pharmacists Take a Larger Role in Substance Use Disorder Care
5












































































































































































































